Streetbeat News

RAIN

Rain Oncology Inc

Employees

Industry

Medicinal and Botanical Manufacturing

rain therapeutics is a san francisco bay area-based biotechnology company, focused on developing small molecule targeted therapeutics for cancer patients that possess a clear, and single, oncogenic driver.

Open

1.24

Mkt cap

44M

Volume

3.7M

High

1.27

P/E Ratio

-0.58

52-wk high

11.32

Low

1.21

Div yield

N/A

52-wk low

0.82

Potential short squeeze plays have been gaining traction, with Aeglea Biotherapeutics, Toro Corp, AirSculpt Technologies, Apollomics, and Greenidge Generation Holdings topping the short squeeze leaderboard. Other stocks to watch include GuardForce AI, Rain Oncology, VCI Global, BullFrog AI Holdings, and Kala Pharmaceuticals. High short interest and steep borrowing costs are common traits that could lead to a short squeeze.

Portfolio Pulse from Chris Katje

July 24, 2023 | 6:05 pm

Rain Oncology's Sep 15 $5 puts sweep near the bid with 2,886 contracts at $3.601, compared to 2,893 open interest. Earnings are estimated to be released on August 3 after market close.

Portfolio Pulse from Charles Gross

June 16, 2023 | 4:28 pm

Mizuho analyst Graig Suvannavejh downgraded Rain Oncology (NASDAQ:RAIN) from Buy to Neutral and lowered the price target from $17 to $1.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 9:11 am

Guidewire Software shares dropped 13.1% after reporting mixed Q3 financial results and issuing FY23 revenue guidance below consensus estimates. Other stocks that moved in Friday's mid-day session include MultiMetaVerse Holdings, Yunji Inc., U Power Limited, Minerva Surgical, and Samsara Inc., among others.

Portfolio Pulse from Lisa Levin

June 02, 2023 | 5:00 pm

Lululemon shares rose 15.1% in pre-market trading after reporting better-than-expected Q1 earnings and sales results. The company expects full-year revenue to be between $9.44 billion and $9.51 billion, up 17% YoY at the mid-point, and EPS to be in the range of $11.74 to $11.94.

Portfolio Pulse from Lisa Levin

June 02, 2023 | 11:58 am

Insiders have recently made significant purchases in four penny stocks: Diversified Healthcare Trust (DHC), Rain Oncology (RAIN), Cronos Group (CRON), and Vaccitech (VACC). These transactions may indicate confidence in the companies' prospects.

Portfolio Pulse from Lisa Levin

June 02, 2023 | 11:17 am

HC Wainwright & Co. analyst Mitchell Kapoor reiterates a Neutral rating on Rain Oncology (NASDAQ:RAIN).

Portfolio Pulse from Benzinga Newsdesk

June 02, 2023 | 10:34 am

During Tuesday's morning session, 137 companies made new 52-week lows. Notable companies include Bristol-Myers Squibb, NovaBay Pharmaceuticals, Smart for Life, and Nemaura Medical.

Portfolio Pulse from Benzinga Insights

May 30, 2023 | 6:13 pm

Roth MKM analyst Raja Kumaraguru downgraded Rain Oncology (NASDAQ:RAIN) from Buy to Neutral and announced a $1.2 price target.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2023 | 3:47 pm

EF Hutton analyst Tony Butler maintains a Hold rating on Rain Oncology (NASDAQ:RAIN) and lowers the price target from $5 to $2.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2023 | 2:50 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.